Low concentrations of adropin are associated with endothelial dysfunction as assessed by flow-mediated dilatation in patients with metabolic syndrome
In individuals with atherosclerotic risk factors, endothelial dysfunction (ED) appears as an early phase in the development of clinical symptoms. Recent studies indicate that adropin, a newly identified peptide, participates in cardiovascular health through the regulation of several metabolic events...
Gespeichert in:
| Veröffentlicht in: | Clinical chemistry and laboratory medicine 2017-01, Vol.55 (1), p.139-144 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 144 |
|---|---|
| container_issue | 1 |
| container_start_page | 139 |
| container_title | Clinical chemistry and laboratory medicine |
| container_volume | 55 |
| creator | Oruc, Coskun U. Akpinar, Yunus E. Dervisoglu, Elmire Amikishiyev, Shirkhan Salmaslıoglu, Artur Gurdol, Figen Omer, Beyhan |
| description | In individuals with atherosclerotic risk factors, endothelial dysfunction (ED) appears as an early phase in the development of clinical symptoms. Recent studies indicate that adropin, a newly identified peptide, participates in cardiovascular health through the regulation of several metabolic events including angiogenesis and blood flow. In this study, we aimed to determine the relation of adropin with biochemical and radiologic parameters which reflect ED such as endothelial nitric oxide synthase (eNOS), endothelin 1 (ET-1), nitric oxide (NO) and flow-mediated dilatation (FMD) along with the routine biochemical measurements in patients recently diagnosed with metabolic syndrome (MetS).
Fasting blood samples from 110 patients with MetS diagnosed according to the NCEP ATP III-2005 criteria were collected to measure the concentrations of adropin and other parameters including the lipid profile, insulin and glucose. Serum NOx concentrations were determined by measuring NO2 plus NO3. FMD test was performed by ultrasonography, and patients were stratified as FMD (+) or (-). Data were compared between these two subgroups and also with matching healthy controls (n=50). Biochemical data were evaluated using Student's t or Mann-Whitney U tests.
Fifty-nine subjects had ED (+) and the remaining 101 subjects were ED (-). In the first group, adropin levels were significantly lower than the latter (2.13±1.05 vs. 3.41±1.63 ng/mL, respectively; p |
| doi_str_mv | 10.1515/cclm-2016-0329 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1826736926</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1826736926</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-c3fefe32d026a90240c329b4b7a2b2e11e3e755aa2ba9c3fd3b69cd360b15f673</originalsourceid><addsrcrecordid>eNptkU1rFjEUhYMotla3LiXgxs3UfE8H3EjxC15wo-uQSe7YlEzymmR4mR_S_2umU0VECOQGnnNOuAehl5RcUknlW2vD3DFCVUc4Gx6hcyp43wnO6eP7WXRKMXqGnpVySwiVUvRP0RnrRS-u-HCO7g7phG2KFmLNpvoUC04TNi6no4_YZMCmlGS9qeDwydcbDNGlegPBm4DdWqYl2k3XuA2FdhweVzyFdOpmcLvS-WDqvT9utsc2tcCyG85QzZiCt7issQXP8Bw9mUwo8OLhvkDfP374dv25O3z99OX6_aGzgonaWT7BBJw5wpQZCBPEtiWMYuwNGxlQChx6KU17maHBjo9qsI4rMlI5qZ5foDe77zGnnwuUqmdfLIRgIqSlaHrFGqUGphr6-h_0Ni05tt9pOjBCBq4ob9TlTtmcSskw6WP2s8mrpkRvhemtML0VprfCmuDVg-0ytmX9wX831IB3O3AyoUJ28CMvaxv-iv-vs5SUNvkvD1mpEA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1920093613</pqid></control><display><type>article</type><title>Low concentrations of adropin are associated with endothelial dysfunction as assessed by flow-mediated dilatation in patients with metabolic syndrome</title><source>MEDLINE</source><source>De Gruyter journals</source><creator>Oruc, Coskun U. ; Akpinar, Yunus E. ; Dervisoglu, Elmire ; Amikishiyev, Shirkhan ; Salmaslıoglu, Artur ; Gurdol, Figen ; Omer, Beyhan</creator><creatorcontrib>Oruc, Coskun U. ; Akpinar, Yunus E. ; Dervisoglu, Elmire ; Amikishiyev, Shirkhan ; Salmaslıoglu, Artur ; Gurdol, Figen ; Omer, Beyhan</creatorcontrib><description>In individuals with atherosclerotic risk factors, endothelial dysfunction (ED) appears as an early phase in the development of clinical symptoms. Recent studies indicate that adropin, a newly identified peptide, participates in cardiovascular health through the regulation of several metabolic events including angiogenesis and blood flow. In this study, we aimed to determine the relation of adropin with biochemical and radiologic parameters which reflect ED such as endothelial nitric oxide synthase (eNOS), endothelin 1 (ET-1), nitric oxide (NO) and flow-mediated dilatation (FMD) along with the routine biochemical measurements in patients recently diagnosed with metabolic syndrome (MetS).
Fasting blood samples from 110 patients with MetS diagnosed according to the NCEP ATP III-2005 criteria were collected to measure the concentrations of adropin and other parameters including the lipid profile, insulin and glucose. Serum NOx concentrations were determined by measuring NO2 plus NO3. FMD test was performed by ultrasonography, and patients were stratified as FMD (+) or (-). Data were compared between these two subgroups and also with matching healthy controls (n=50). Biochemical data were evaluated using Student's t or Mann-Whitney U tests.
Fifty-nine subjects had ED (+) and the remaining 101 subjects were ED (-). In the first group, adropin levels were significantly lower than the latter (2.13±1.05 vs. 3.41±1.63 ng/mL, respectively; p<0.001) and independently associated with FMD positivity as assessed by the logistic regression analysis.
Low adropin level in circulation is related to ED and has a close association with FMD. Any alterations in its level may be of help in order to assess the development of ED before the occurrence of clinical symptoms in patients with metabolic syndrome.</description><identifier>ISSN: 1434-6621</identifier><identifier>EISSN: 1437-4331</identifier><identifier>DOI: 10.1515/cclm-2016-0329</identifier><identifier>PMID: 27474839</identifier><language>eng</language><publisher>Germany: De Gruyter</publisher><subject>adropin ; Angiogenesis ; Arteriosclerosis ; Atherosclerosis ; Biochemistry ; Blood flow ; Blood Proteins - metabolism ; Circulation ; Dilatation ; endothelial dysfunction ; endothelial nitric oxide synthase ; Endothelin 1 ; Endothelium, Vascular - metabolism ; Endothelium, Vascular - pathology ; Fasting ; flow-mediated dilatation ; Glucose ; Humans ; Insulin ; Low concentrations ; Metabolic syndrome ; Metabolic Syndrome - diagnosis ; Metabolic Syndrome - metabolism ; Nitric oxide ; Nitric-oxide synthase ; Nitrogen oxides ; Patients ; Peptides - blood ; Peptides - metabolism ; Regression analysis ; Risk analysis ; Risk factors ; Stretching ; Subgroups ; Ultrasound</subject><ispartof>Clinical chemistry and laboratory medicine, 2017-01, Vol.55 (1), p.139-144</ispartof><rights>Copyright Walter De Gruyter & Company 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c424t-c3fefe32d026a90240c329b4b7a2b2e11e3e755aa2ba9c3fd3b69cd360b15f673</citedby><cites>FETCH-LOGICAL-c424t-c3fefe32d026a90240c329b4b7a2b2e11e3e755aa2ba9c3fd3b69cd360b15f673</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.degruyter.com/document/doi/10.1515/cclm-2016-0329/pdf$$EPDF$$P50$$Gwalterdegruyter$$H</linktopdf><linktohtml>$$Uhttps://www.degruyter.com/document/doi/10.1515/cclm-2016-0329/html$$EHTML$$P50$$Gwalterdegruyter$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,66497,68281</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27474839$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Oruc, Coskun U.</creatorcontrib><creatorcontrib>Akpinar, Yunus E.</creatorcontrib><creatorcontrib>Dervisoglu, Elmire</creatorcontrib><creatorcontrib>Amikishiyev, Shirkhan</creatorcontrib><creatorcontrib>Salmaslıoglu, Artur</creatorcontrib><creatorcontrib>Gurdol, Figen</creatorcontrib><creatorcontrib>Omer, Beyhan</creatorcontrib><title>Low concentrations of adropin are associated with endothelial dysfunction as assessed by flow-mediated dilatation in patients with metabolic syndrome</title><title>Clinical chemistry and laboratory medicine</title><addtitle>Clin Chem Lab Med</addtitle><description>In individuals with atherosclerotic risk factors, endothelial dysfunction (ED) appears as an early phase in the development of clinical symptoms. Recent studies indicate that adropin, a newly identified peptide, participates in cardiovascular health through the regulation of several metabolic events including angiogenesis and blood flow. In this study, we aimed to determine the relation of adropin with biochemical and radiologic parameters which reflect ED such as endothelial nitric oxide synthase (eNOS), endothelin 1 (ET-1), nitric oxide (NO) and flow-mediated dilatation (FMD) along with the routine biochemical measurements in patients recently diagnosed with metabolic syndrome (MetS).
Fasting blood samples from 110 patients with MetS diagnosed according to the NCEP ATP III-2005 criteria were collected to measure the concentrations of adropin and other parameters including the lipid profile, insulin and glucose. Serum NOx concentrations were determined by measuring NO2 plus NO3. FMD test was performed by ultrasonography, and patients were stratified as FMD (+) or (-). Data were compared between these two subgroups and also with matching healthy controls (n=50). Biochemical data were evaluated using Student's t or Mann-Whitney U tests.
Fifty-nine subjects had ED (+) and the remaining 101 subjects were ED (-). In the first group, adropin levels were significantly lower than the latter (2.13±1.05 vs. 3.41±1.63 ng/mL, respectively; p<0.001) and independently associated with FMD positivity as assessed by the logistic regression analysis.
Low adropin level in circulation is related to ED and has a close association with FMD. Any alterations in its level may be of help in order to assess the development of ED before the occurrence of clinical symptoms in patients with metabolic syndrome.</description><subject>adropin</subject><subject>Angiogenesis</subject><subject>Arteriosclerosis</subject><subject>Atherosclerosis</subject><subject>Biochemistry</subject><subject>Blood flow</subject><subject>Blood Proteins - metabolism</subject><subject>Circulation</subject><subject>Dilatation</subject><subject>endothelial dysfunction</subject><subject>endothelial nitric oxide synthase</subject><subject>Endothelin 1</subject><subject>Endothelium, Vascular - metabolism</subject><subject>Endothelium, Vascular - pathology</subject><subject>Fasting</subject><subject>flow-mediated dilatation</subject><subject>Glucose</subject><subject>Humans</subject><subject>Insulin</subject><subject>Low concentrations</subject><subject>Metabolic syndrome</subject><subject>Metabolic Syndrome - diagnosis</subject><subject>Metabolic Syndrome - metabolism</subject><subject>Nitric oxide</subject><subject>Nitric-oxide synthase</subject><subject>Nitrogen oxides</subject><subject>Patients</subject><subject>Peptides - blood</subject><subject>Peptides - metabolism</subject><subject>Regression analysis</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Stretching</subject><subject>Subgroups</subject><subject>Ultrasound</subject><issn>1434-6621</issn><issn>1437-4331</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkU1rFjEUhYMotla3LiXgxs3UfE8H3EjxC15wo-uQSe7YlEzymmR4mR_S_2umU0VECOQGnnNOuAehl5RcUknlW2vD3DFCVUc4Gx6hcyp43wnO6eP7WXRKMXqGnpVySwiVUvRP0RnrRS-u-HCO7g7phG2KFmLNpvoUC04TNi6no4_YZMCmlGS9qeDwydcbDNGlegPBm4DdWqYl2k3XuA2FdhweVzyFdOpmcLvS-WDqvT9utsc2tcCyG85QzZiCt7issQXP8Bw9mUwo8OLhvkDfP374dv25O3z99OX6_aGzgonaWT7BBJw5wpQZCBPEtiWMYuwNGxlQChx6KU17maHBjo9qsI4rMlI5qZ5foDe77zGnnwuUqmdfLIRgIqSlaHrFGqUGphr6-h_0Ni05tt9pOjBCBq4ob9TlTtmcSskw6WP2s8mrpkRvhemtML0VprfCmuDVg-0ytmX9wX831IB3O3AyoUJ28CMvaxv-iv-vs5SUNvkvD1mpEA</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Oruc, Coskun U.</creator><creator>Akpinar, Yunus E.</creator><creator>Dervisoglu, Elmire</creator><creator>Amikishiyev, Shirkhan</creator><creator>Salmaslıoglu, Artur</creator><creator>Gurdol, Figen</creator><creator>Omer, Beyhan</creator><general>De Gruyter</general><general>Walter De Gruyter & Company</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T7</scope><scope>7TK</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20170101</creationdate><title>Low concentrations of adropin are associated with endothelial dysfunction as assessed by flow-mediated dilatation in patients with metabolic syndrome</title><author>Oruc, Coskun U. ; Akpinar, Yunus E. ; Dervisoglu, Elmire ; Amikishiyev, Shirkhan ; Salmaslıoglu, Artur ; Gurdol, Figen ; Omer, Beyhan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-c3fefe32d026a90240c329b4b7a2b2e11e3e755aa2ba9c3fd3b69cd360b15f673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>adropin</topic><topic>Angiogenesis</topic><topic>Arteriosclerosis</topic><topic>Atherosclerosis</topic><topic>Biochemistry</topic><topic>Blood flow</topic><topic>Blood Proteins - metabolism</topic><topic>Circulation</topic><topic>Dilatation</topic><topic>endothelial dysfunction</topic><topic>endothelial nitric oxide synthase</topic><topic>Endothelin 1</topic><topic>Endothelium, Vascular - metabolism</topic><topic>Endothelium, Vascular - pathology</topic><topic>Fasting</topic><topic>flow-mediated dilatation</topic><topic>Glucose</topic><topic>Humans</topic><topic>Insulin</topic><topic>Low concentrations</topic><topic>Metabolic syndrome</topic><topic>Metabolic Syndrome - diagnosis</topic><topic>Metabolic Syndrome - metabolism</topic><topic>Nitric oxide</topic><topic>Nitric-oxide synthase</topic><topic>Nitrogen oxides</topic><topic>Patients</topic><topic>Peptides - blood</topic><topic>Peptides - metabolism</topic><topic>Regression analysis</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Stretching</topic><topic>Subgroups</topic><topic>Ultrasound</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oruc, Coskun U.</creatorcontrib><creatorcontrib>Akpinar, Yunus E.</creatorcontrib><creatorcontrib>Dervisoglu, Elmire</creatorcontrib><creatorcontrib>Amikishiyev, Shirkhan</creatorcontrib><creatorcontrib>Salmaslıoglu, Artur</creatorcontrib><creatorcontrib>Gurdol, Figen</creatorcontrib><creatorcontrib>Omer, Beyhan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical chemistry and laboratory medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oruc, Coskun U.</au><au>Akpinar, Yunus E.</au><au>Dervisoglu, Elmire</au><au>Amikishiyev, Shirkhan</au><au>Salmaslıoglu, Artur</au><au>Gurdol, Figen</au><au>Omer, Beyhan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Low concentrations of adropin are associated with endothelial dysfunction as assessed by flow-mediated dilatation in patients with metabolic syndrome</atitle><jtitle>Clinical chemistry and laboratory medicine</jtitle><addtitle>Clin Chem Lab Med</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>55</volume><issue>1</issue><spage>139</spage><epage>144</epage><pages>139-144</pages><issn>1434-6621</issn><eissn>1437-4331</eissn><abstract>In individuals with atherosclerotic risk factors, endothelial dysfunction (ED) appears as an early phase in the development of clinical symptoms. Recent studies indicate that adropin, a newly identified peptide, participates in cardiovascular health through the regulation of several metabolic events including angiogenesis and blood flow. In this study, we aimed to determine the relation of adropin with biochemical and radiologic parameters which reflect ED such as endothelial nitric oxide synthase (eNOS), endothelin 1 (ET-1), nitric oxide (NO) and flow-mediated dilatation (FMD) along with the routine biochemical measurements in patients recently diagnosed with metabolic syndrome (MetS).
Fasting blood samples from 110 patients with MetS diagnosed according to the NCEP ATP III-2005 criteria were collected to measure the concentrations of adropin and other parameters including the lipid profile, insulin and glucose. Serum NOx concentrations were determined by measuring NO2 plus NO3. FMD test was performed by ultrasonography, and patients were stratified as FMD (+) or (-). Data were compared between these two subgroups and also with matching healthy controls (n=50). Biochemical data were evaluated using Student's t or Mann-Whitney U tests.
Fifty-nine subjects had ED (+) and the remaining 101 subjects were ED (-). In the first group, adropin levels were significantly lower than the latter (2.13±1.05 vs. 3.41±1.63 ng/mL, respectively; p<0.001) and independently associated with FMD positivity as assessed by the logistic regression analysis.
Low adropin level in circulation is related to ED and has a close association with FMD. Any alterations in its level may be of help in order to assess the development of ED before the occurrence of clinical symptoms in patients with metabolic syndrome.</abstract><cop>Germany</cop><pub>De Gruyter</pub><pmid>27474839</pmid><doi>10.1515/cclm-2016-0329</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1434-6621 |
| ispartof | Clinical chemistry and laboratory medicine, 2017-01, Vol.55 (1), p.139-144 |
| issn | 1434-6621 1437-4331 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1826736926 |
| source | MEDLINE; De Gruyter journals |
| subjects | adropin Angiogenesis Arteriosclerosis Atherosclerosis Biochemistry Blood flow Blood Proteins - metabolism Circulation Dilatation endothelial dysfunction endothelial nitric oxide synthase Endothelin 1 Endothelium, Vascular - metabolism Endothelium, Vascular - pathology Fasting flow-mediated dilatation Glucose Humans Insulin Low concentrations Metabolic syndrome Metabolic Syndrome - diagnosis Metabolic Syndrome - metabolism Nitric oxide Nitric-oxide synthase Nitrogen oxides Patients Peptides - blood Peptides - metabolism Regression analysis Risk analysis Risk factors Stretching Subgroups Ultrasound |
| title | Low concentrations of adropin are associated with endothelial dysfunction as assessed by flow-mediated dilatation in patients with metabolic syndrome |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T07%3A14%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Low%20concentrations%20of%20adropin%20are%20associated%20with%20endothelial%20dysfunction%20as%20assessed%20by%20flow-mediated%20dilatation%20in%20patients%20with%20metabolic%20syndrome&rft.jtitle=Clinical%20chemistry%20and%20laboratory%20medicine&rft.au=Oruc,%20Coskun%20U.&rft.date=2017-01-01&rft.volume=55&rft.issue=1&rft.spage=139&rft.epage=144&rft.pages=139-144&rft.issn=1434-6621&rft.eissn=1437-4331&rft_id=info:doi/10.1515/cclm-2016-0329&rft_dat=%3Cproquest_cross%3E1826736926%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1920093613&rft_id=info:pmid/27474839&rfr_iscdi=true |